Literature DB >> 10397262

The human p53 negative regulatory domain mediates inhibition of reporter gene transactivation in yeast lacking thioredoxin reductase.

G F Merrill1, P Dowell, G D Pearson.   

Abstract

Stimulation of target gene transcription by human p53 is inhibited in budding yeast lacking the TRR1 gene encoding thioredoxin reductase. LexA/p53 fusion proteins were used to study the basis for thioredoxin reductase dependence. A fusion protein containing all 393 of the residues of p53 efficiently and specifically stimulated transcription of a LexOP-LacZ reporter gene in wild-type yeast but was several-fold less effective in delta trr1 yeast lacking the thioredoxin reductase gene. Thus, even when p53 was tethered to a reporter gene by a heterologous DNA-binding domain, reporter gene transactivation remained dependent on thioredoxin reductase. A fusion protein containing only the activation domain of p53 stimulated reporter gene transcription equally in wild-type and delta trr1 cells, suggesting that p53 residues downstream from the activation domain created the requirement for thioredoxin reductase. Experiments using additional LexA/p53 truncation mutations indicated that the p53 negative regulatory domain, rather than the DNA-binding or oligomerization domains, created the requirement for thioredoxin reductase. The fusion protein results suggested that, under oxidative conditions, the negative regulatory domain inhibited the ability of DNA-bound p53 to stimulate transcription. However, deletion of the negative regulatory domain did not alleviate the requirement of non-LexA-containing p53 for thioredoxin reductase. The results, thus, suggest that oxidative conditions inhibit both DNA binding and transactivation by p53, and that inhibition of the latter requires the negative regulatory domain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397262

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Redox modification of cell signaling in the cardiovascular system.

Authors:  Dan Shao; Shin-ichi Oka; Christopher D Brady; Judith Haendeler; Philip Eaton; Junichi Sadoshima
Journal:  J Mol Cell Cardiol       Date:  2011-09-17       Impact factor: 5.000

2.  Thioredoxin reductase 1 deficiency enhances selenite toxicity in cancer cells via a thioredoxin-independent mechanism.

Authors:  Ryuta Tobe; Min-Hyuk Yoo; Noelia Fradejas; Bradley A Carlson; Soledad Calvo; Vadim N Gladyshev; Dolph L Hatfield
Journal:  Biochem J       Date:  2012-08-01       Impact factor: 3.857

Review 3.  Selenoproteins that function in cancer prevention and promotion.

Authors:  Dolph L Hatfield; Min-Hyuk Yoo; Bradley A Carlson; Vadim N Gladyshev
Journal:  Biochim Biophys Acta       Date:  2009-03-09

Review 4.  Selenoproteins: molecular pathways and physiological roles.

Authors:  Vyacheslav M Labunskyy; Dolph L Hatfield; Vadim N Gladyshev
Journal:  Physiol Rev       Date:  2014-07       Impact factor: 37.312

5.  Alteration of thioredoxin reductase 1 levels in elucidating cancer etiology.

Authors:  Min-Hyuk Yoo; Bradley A Carlson; Petra Tsuji; Robert Irons; Vadim N Gladyshev; Dolph L Hatfield
Journal:  Methods Enzymol       Date:  2010-06-20       Impact factor: 1.600

Review 6.  Targeting selenium metabolism and selenoproteins: novel avenues for drug discovery.

Authors:  Sarah Elizabeth Jackson-Rosario; William Thomas Self
Journal:  Metallomics       Date:  2009-10-27       Impact factor: 4.526

7.  Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure.

Authors:  Gustav Nilsonne; Eric Olm; Adam Szulkin; Filip Mundt; Agnes Stein; Branka Kocic; Anna-Klara Rundlöf; Aristi P Fernandes; Mikael Björnstedt; Katalin Dobra
Journal:  J Exp Clin Cancer Res       Date:  2009-06-29

8.  Effect of thioredoxin deletion and p53 cysteine replacement on human p53 activity in wild-type and thioredoxin reductase null yeast.

Authors:  Christopher S Stoner; George D Pearson; Ahmet Koç; Jason R Merwin; Nathan I Lopez; Gary F Merrill
Journal:  Biochemistry       Date:  2009-09-29       Impact factor: 3.162

9.  Thioredoxin reductase 1 protects against chemically induced hepatocarcinogenesis via control of cellular redox homeostasis.

Authors:  Bradley A Carlson; Min-Hyuk Yoo; Ryuta Tobe; Charles Mueller; Salvador Naranjo-Suarez; Victoria J Hoffmann; Vadim N Gladyshev; Dolph L Hatfield
Journal:  Carcinogenesis       Date:  2012-07-12       Impact factor: 4.944

10.  p53 Interacts with RNA polymerase II through its core domain and impairs Pol II processivity in vivo.

Authors:  Sunyoung Kim; Sri Kripa Balakrishnan; David S Gross
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.